Celiac disease (CD) is a gluten-sensitive, immunemediated chronic enteropathy with a wide range of manifestations of variable severity. It is triggered by the ingestion of gliadin fractions of wheat gluten and similar alcohol-soluble proteins (prolamines) of barley and rye in genetically susceptible subjects. The subsequent immune reaction leads to small bowel inflammation and villous atrophy. Adherence to a gluten-free diet (GFD) is followed by amelioration or normalization of the villous architecture. CD represents a ''unique'' autoimmune disease in that the environmental factor triggering the immune response (gluten) is known. CD not only affects the gut but is also a systemic disease that may cause injury to extraintestinal organs as well. Human leukocyte antigen (HLA) status appears to be the strongest genetic determinant of risk for celiac autoimmunity, because of the role that specific HLA class II alleles play in the presentation of gluten to T cells. Of the affected individuals, 95% have either DQ2 (HLA-DQA1Ã05-DQB1Ã02) or DQ8 (HLA-DQA1Ã03-DQB1Ã0302), in comparison with the general population in which about 30% to 35% have either DQ2 or DQ8 (1, 2) . Besides HLA II class genes, there is evidence for involvement of other genes located on chromosomes 2 (2q33), 5 (5q31-q33), and 19 (19p13.1) , and in the region harboring interleukin-2 (IL-2) and IL-21 (3) (4) (5) (6) .
The true prevalence of CD is difficult to estimate because of its variable clinical presentation, and many patients can have few or no symptoms. With a better appreciation of its clinical complexity and the availability of sensitive and specific screening tests, CD is now considered a public health problem worldwide. CD affects as much as 0.5% to 1.0% of European or European ancestry populations, but most cases remain undiagnosed (7) (8) (9) (10) (11) .
CONTROVERSIAL ISSUES Diagnosis

Serology Tests
The tissue transglutaminase antibody (tTG) enzymelinked immunoassay is the universally recommended screening test for CD (3, 4) . The occurrence of both immunoglobulin (Ig)A deficiency and CD in the same individual varies between 2% and 10%; thus, measurement of total serum IgA is necessary to interpret low tTGIgA. In cases of IgA deficiency, testing with tTG-IgG is recommended to detect CD. Because the inferior accuracy of the antigliadin assays, the use of this test no longer is routinely recommended. The use of deamidated gliadin to increase specificity of the antigliadin assay awaits confirmation by large-scale validation.
Point of Contact (POC) Tests
Point of contact (POC) tests are in vitro diagnostic devices used outside the laboratory close to the site of patient care. The demand for POC testing is increasing, because of advances in technology and the need for rapid tests. Three rapid methods are currently available for detection of serum or whole blood tTGA with good sensitivity and specificity (12) (13) (14) . These tests can be performed on a drop of whole blood, allow a visual reading of the result after a few minutes (15) , and represent a valuable alternative to the traditional serological tests for CD. However, the risk that POC tests can lead to self-diagnosis and implantation of a GFD without an intestinal biopsy confirmation needs to be scrutinized in future research.
Genetic Tests
CD patients lacking HLA-DQ2 or DQ8 are exceptional, and the lack of both haplotypes strongly argues against the diagnosis of CD (3). HLA typing for DQ2/DQ8 has a high sensitivity but low specificity for CD, indicating a poor positive predictive value, but a high negative predictive value for the disease. If in the future the ''CD cluster'' of predisposed genes is identified, this may form a useful tool to detect CD. Determining whether specific genotypes can affect type and/or age of onset of symptoms and possible associated complications would be an important objective for future research.
Intestinal Biopsy
Small bowel biopsy has remained the confirmatory cornerstone test for CD (16) . Esophagogastroduodenoscopy is the preferred diagnostic technique, allowing multiple intestinal biopsies (4) (5) (6) . Interpretation of the biopsy requires an expert pathologist to score the most severely affected biopsy (17) . Marsh type 1 alterations, or increased intraepithelial lymphocytes (>25/100 enterocytes), are nonspecific in children, especially in children from developing countries (18) , but in the setting of positive tTGA and symptoms a trial of GFD may be warranted. Both pediatric and adult studies have suggested algorithms for the detection of CD without a biopsy (19, 20) in those with typical gastrointestinal symptoms and high titer of tTGA. These findings need to be confirmed by larger population studies to be validated as routine clinical practice.
Screening
Targeted Screening of High-risk Groups
There is evidence that CD should be tested in children with persistent gastrointestinal symptoms such as diarrhea, recurrent abdominal pain, constipation, and vomiting, as well as in children with nongastrointestinal symptoms of CD such as dermatitis herpetiformis, dental enamel hypoplasia of permanent teeth, osteoporosis, short stature, delayed puberty, and iron-deficient anemia (14) . CD testing also is recommended for asymptomatic children who have conditions associated with CD such as type 1 diabetes mellitus, autoimmune thyroiditis, Down syndrome, Turner syndrome, Williams syndrome, and selective IgA deficiency, as well as first-degree relatives with CD. Testing of asymptomatic children who belong to groups at risk should begin at around 3 to 4 years of age, provided they have had an adequate gluten-containing diet for at least 1 year before testing (21) .
Mass Screening
The prevalence of CD exceeds by far that of a number of diseases for which mass screening programs are in place (22) . CD has a broad spectrum of symptoms and the disease is difficult to identify on clinical grounds alone, often resulting in delayed or missed diagnosis. Health consequences of untreated CD include anemia, delayed puberty, growth impairment, hypertransaminasemia, neuropsychiatric disturbance, depression, epilepsy with cerebral calcifications, low bone mineral density and dental enamel hypoplasia, and autoimmune diseases, depending on the duration of gluten exposure (23) . Two severe late complications of CD are malignancy and osteoporosis. CD has an accepted treatment, the GFD. Mass screening of the general population is 1 way to identify people with CD at an early stage. However, despite fulfilling many of the general screening criteria, mass screening for CD includes several controversial factors that keep a debate ongoing (24, 25) .
CELIAC DISEASE IN THE DEVELOPING WORLD CD Causal Factors Show a Worldwide Distribution
The principal genetic (HLA DQ2 and DQ8) and environmental (gluten) factors responsible for the development of CD show a worldwide distribution (26) . A variable frequency of either high (eg, DQ2 in homozygosity) or low/moderate risk (eg, DQ8) genotypes could explain the variable prevalence of CD that has been reported in different parts of the world.
CD Is Increasingly Reported From the Developing World
Epidemiological studies have shown that CD is common in many developing countries (27) . The presence of CD is long established in many South American countries that are mostly populated by individuals of European origin (10, 28) .
Although the frequency of CD in many parts of Africa is still unknown, it is clear that this condition is present in the African continent. The highest CD prevalence in the world (5.6%) occurs in an African population originally living in western Sahara, the Saharawi, of Arab-Berber origin (29) . The reasons for this may be related to the high level of consanguinity and the high frequency of HLA-DQ2 and-DQ8 in the Saharawi population (30) . Gluten consumption is also high. CD also is a common and usually undiagnosed disorder among Egyptian children (31) . In a recent mass screening for CD on 6284 children in Tunisia, a prevalence of 1:157 was found (32) . Indirect evidence suggests that CD is not a rare disorder in other northern African countries (33, 34) . CD is a frequent disorder also in the Middle East (35) . In studies from Iran, Iraq, Saudi Arabia, and Kuwait, CD accounted for 20% and 18.5% of cases with chronic diarrhea in adults and children, respectively. In a study from Jordan, the high incidence of CD was related to the large wheat consumption of the population (135 kg/head/year) (36) . The overall prevalence of CD in India is not known, but is likely to be high in a part of northern India where wheat is a staple food (26) . There are only anecdotal reports of CD in Far East countries. Given the low prevalence of HLA predisposing genes DQ2/DQ8 and the low/absent gluten consumption, reduced disease prevalence should be expected in those populations.
The burden of disease caused by CD in developing countries is largely underestimated. Reasons for this include the belief that CD does not exist in developing countries; poor awareness of the clinical variability of CD; scarcity of diagnostic facilities; and more emphasis on other causes of small intestinal damage, such as intestinal tuberculosis and environmental enteropathy (26) . It also is possible that the prevalence of CD is increasing in some developing countries because of increasing consumption of gluten-containing cereals.
CD Clinical Spectrum in Developing Countries
The typical child with CD in developing countries may resemble the picture of chronic protein-energy malnutrition known as kwashiorkor. The predominant clinical manifestations of CD among Saharawi children are chronic diarrhea, abdominal distension, growth failure, depressed mood, and loss of appetite (29) . In children affected with CD from India, the majority (84%) presented with diarrhea; other features were failure to thrive in 91%, anemia in 84%, wasting in 87%, and stunting in 60% of cases.
Although symptomatic forms seem to be more common in developing countries, serological screening studies in these regions have shown many cases present with mild complaints or no symptoms at all.
Reliability of Diagnostic Tools
Studies in South America, the Middle East, and India have shown that both the endomysium antibodies and tTG are highly specific markers of celiac autoimmunity in subjects living in areas with high rate of infectious and/or parasitic diarrhea. The recent introduction of a quick test for POC determination of IgA class anti-tTG could overcome, at least in part, problems related to the scarcity of sophisticated diagnostic equipment (12) .
Treatment Strategies
To be effective, implementation of a GFD has to take local dietary habits into account by using naturally glutenfree products that are locally available, such as millet (Africa), manioc (South America), and rice. To avoid cross-contamination with gluten, dedicated machinery needs to be used to mill these grains. The treatment strategy also should include education for doctors, nurses, dieticians, school personnel, affected families, and the general population. Finally, creation of patient support groups can provide psychological support, a valuable source of information.
Treatment Alternatives to the Gluten-free Diet
A GFD is effective and safe and at present is the only available treatment for CD. Any alternative treatment in the future must have a safety and effective profile equivalent to that of the GFD, but with the advantage of increased compliance, quality of life, and feasibility in developing countries in which implementation of a GFD is complicated by formidable economical, cultural, and distribution difficulties.
Enzyme Therapy
Gluten peptides are resistant to digestion by pancreatic and brush border proteases (37) . Enzyme supplement therapy with bacterial prolyl endopeptidases has been proposed to promote digestion of cereal proteins and thus destroy T cell multipotent epitopes. It remains to be assessed to what extent such intraluminal digestion is effective in practice. An alternative approach is based on a pretreatment of gluten-containing food with bacterialderived peptidase (38) . CD patients tolerated breads produced with sourdough (lactobacillus digested) better than those with Baker's yeast (39) . Another approach to produce nontoxic, wheat-based products is transamidation of gluten peptides by tTG, because it has been shown that these peptides inhibit interferon gamma expression in intestinal T-cell lines (40) .
Engineered Grains and Inhibitory Gliadin Peptides
Breeding programs and/or transgenic technology may lead to production of wheat that is devoid of biologically active peptide sequences. Site-directed mutagenesis of wheat, which would not affect the baking properties, also has been proposed, although the number and the repetition of such sequences in wheat render this approach difficult.
Immunomodulatory Strategies
The autoantigenic tTG is mainly expressed in the lamina propria and catalyzes transamidation of gluten peptides (glutamine to glutamic acid), increasing their rate of phagocytosis by antigen-presenting cells (41) . Selective inhibition of tTG in the small intestine may represent a useful therapeutic strategy in CD.
Correction of the Intestinal Barrier Defect
The barrier function and ability to regulate the trafficking of macromolecules between the environment and the host is an important function of the small bowel. Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to non-self-antigens (42) . The correction of the intestinal barrier defects may represent an innovative therapeutic alternative in CD, because small intestinal permeability abnormalities are seen in untreated CD patients, which return to normal on a GFD (43) . The use of the zonulin inhibitor AT1001 to correct intestinal barrier defects already has been successfully explored in an animal model of autoimmunity (44) . Recently, AT1001 has been shown to be well tolerated and to reduce gluten-induced intestinal barrier dysfunction, proinflammatory cytokine production, and gastrointestinal symptoms in celiac patients (45) .
RESEARCH AGENDA
In 2007 the European platform on CD CDEUSSAformed by 103 key stakeholders from 27 countries, representing among others research, food industry, and public health and patient organizations-identified 4 CD topics (clinical aspects, treatment, prevention, and public health) in need of investigation during the next few years. These research areas and related topics have been proposed to the European Community as high priority research to improve the health status of the European population and are presented in Table 1 (46) . The overall research goal should be to improve the quality of life of the population by implementing primary prevention strategies, early diagnosis, and improved treatments for CD. Strategies for effective case-finding, and even mass screening efforts, should be explored to decrease the large proportion of undiagnosed and untreated CD subjects. Such efforts should include evaluation of short-and long-term consequences both for participating individuals and society, also considering health economic aspects, particularly in developing countries. The magnitude of the CD problem worldwide and trends over time should be established. New treatment strategies need to be developed. Expected results are the identification of nutritional, immunomodulatory, and biochemical strategies useful to successfully treat CD subjects. The option of primary prevention should be fully explored, which requires combined epidemiological, clinical, and basic science research efforts. Such studies also should consider the importance of gene-environment interactions in the development of CD. To achieve these goals, and have a significant impact on the public health problem of CD, a collaboration of the stakeholders is fundamental, including research and patient organizations as well as industries within both diagnostics and food production.
CONSENSUS GUIDELINES
CD is an immune-mediated enteropathy that can affect any system or organ and that can present itself with a wide range of clinical manifestations of variable severity CD represents a unique autoimmune disease in that the environmental factor triggering the immune response (gluten) is known CD is a complex genetic disorder and HLA status appears to be the strongest genetic determinant of risk for celiac autoimmunity The diagnosis of CD is based on specific and sensitive screening tests (particularly in at-risk populations) and an intestinal biopsy as a confirmatory test CD is not confined to whites of European origin. Rather, CD is extremely frequent in any area of the world where both genetic determinants (HLA class II genes) and environmental trigger (gluten) are present CD is one of the most frequent genetic disorders of humankind, affecting 0.5% to 1% of the general population Nevertheless, CD remains highly underestimated, particularly in developing countries, where its clinical presentation can be mistaken for pathologies (infections, malnutrition, etc) that have been considered more prevalent The best approach to search for CD patients (mass screening vs case-finding) remains controversial; however, cost-benefit analyses and issues related to treatment compliance suggest that case-finding is the most appropriate approach The implementation of a GFD remains the most effective treatment for CD; however, treating the disease with GFD in a developing country with limited resources can be extremely difficult or not doable at all Regardless of the socioeconomic realities, there are a number of drawbacks to a lifelong GFD possibly affecting the quality of life of CD patients New knowledge has opened the potential of new preventive and therapeutic strategies for CD that are being explored 
